## Michael B. Barton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7234464/publications.pdf

Version: 2024-02-01

230 papers

10,143 citations

76031 42 h-index 94 g-index

233 all docs

233 docs citations

times ranked

233

10693 citing authors

#	Article	IF	CITATIONS
1	Lung cancer treatment patterns and factors relating to systemic therapy use in Australia. Asia-Pacific Journal of Clinical Oncology, 2022, 18, .	0.7	6
2	Resource stratified guidelines for cancer: Are they all the same? Interguideline concordance for systemic treatment recommendations. International Journal of Cancer, 2022, 150, 91-99.	2.3	4
3	Prioritising access to cancer drugs. Lancet Oncology, The, 2022, 23, e1.	5.1	O
4	Variability of gross tumour volume delineation: MRI and CT based tumour and lymph node delineation for lung radiotherapy. Radiotherapy and Oncology, 2022, 167, 292-299.	0.3	6
5	Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort. Journal of Thoracic Oncology, 2022, 17, 688-699.	0.5	24
6	Magnetic resonance imaging (MRI) guided proton therapy: A review of the clinical challenges, potential benefits and pathway to implementation. Radiotherapy and Oncology, 2022, 170, 37-47.	0.3	15
7	Development of an age- and comorbidity adjusted- optimal radiotherapy utilisation rate for women with breast cancer. Journal of Geriatric Oncology, 2022, 13, 844-849.	0.5	3
8	Great expectations or waiting for Godot? Time for development of a near realâ€time national reporting system of radiotherapy utilisation. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 826-829.	0.9	1
9	Radiotherapy service need in the Pacific Island countries. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e217-e225.	0.7	4
10	The value of firstâ€ine chemotherapy and targeted therapy in the treatment of breast cancer. European Journal of Cancer Care, 2021, 30, e13352.	0.7	4
11	Australia and New Zealand's responsibilities in improving oncology services in the Asiaâ€Pacific: A call to action. Asia-Pacific Journal of Clinical Oncology, 2021, , .	0.7	6
12	Evidence-based benchmarks for use of cancer surgery in high-income countries: a population-based analysis. Lancet Oncology, The, 2021, 22, 173-181.	5.1	8
13	Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study. Lancet Oncology, The, 2021, 22, 182-189.	5.1	47
14	Patterns of care for men with prostate cancer: the 45 and Up Study. Medical Journal of Australia, 2021, 214, 271-278.	0.8	17
15	Hypofractionated radiotherapy in the real-world setting: An international ESTRO-GIRO survey. Radiotherapy and Oncology, 2021, 157, 32-39.	0.3	51
16	Multi-parametric magnetic resonance imaging assessment of whole tumour heterogeneity for chemoradiotherapy response prediction in rectal cancer. Physics and Imaging in Radiation Oncology, 2021, 18, 26-33.	1.2	8
17	Equity should know no borders: The role of Australasian radiation oncologists in supporting radiation oncology services in low―and middleâ€income countries in the Asiaâ€Pacific. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 410-417.	0.9	4
18	Are NCCN Resource-Stratified Guidelines for Breast Cancer Systemic Therapy Achievable? A Population-Based Study of Global Need and Economic Impact. JCO Global Oncology, 2021, 7, 1074-1083.	0.8	3

#	Article	IF	CITATIONS
19	Implementation of 3D conformal radiotherapy technology at the National Cancer Centre Mongolia: A successful Asiaâ€Pacific collaborative initiative. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 454-459.	0.9	3
20	Artificial intelligence in medical imaging and radiation oncology: Opportunities and challenges. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 481-485.	0.9	7
21	The Modernization of Radiation Therapy Services in Cambodia: A Model of International Collaboration. International Journal of Radiation Oncology Biology Physics, 2021, 111, 14-22.	0.4	O
22	Trends in the use of shortâ€course radiation therapy for rectal cancer in New South Wales, Australia. Journal of Medical Imaging and Radiation Oncology, 2021, , .	0.9	2
23	Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications. Radiotherapy and Oncology, 2020, 152, 70-77.	0.3	10
24	The Radiation Oncology trainee research programme is working well, so can anything else be done to help our trainees acquire research skills?. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 303-305.	0.9	1
25	Health Economic and Health Service Issues of Palliative Radiotherapy. Clinical Oncology, 2020, 32, 775-780.	0.6	5
26	Factors Associated With Radiotherapy Utilisation In New South Wales, Australia: Results From The 45 and Up Study. Clinical Oncology, 2020, 32, 282-291.	0.6	8
27	Multicenter evaluation of MRIâ€based radiomic features: A phantom study. Medical Physics, 2020, 47, 3054-3063.	1.6	44
28	Quality management in radiation therapy: A 15 year review of incident reporting in two integrated cancer centres. Technical Innovations and Patient Support in Radiation Oncology, 2020, 14, 15-20.	0.6	8
29	Factors affecting radiotherapy utilisation in geriatric oncology patients in NSW, Australia. Technical Innovations and Patient Support in Radiation Oncology, 2020, 16, 17-23.	0.6	6
30	Cancer control in the Pacific: big challenges facing small island states. Lancet Oncology, The, 2019, 20, e475-e492.	5.1	31
31	Cancer control in the Caribbean island countries and territories: some progress but the journey continues. Lancet Oncology, The, 2019, 20, e503-e521.	5.1	25
32	Enhancing Career Paths for Tomorrow's Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2019, 105, 52-63.	0.4	20
33	Correlation of ultra-high field MRI with histopathology for evaluation of rectal cancer heterogeneity. Scientific Reports, 2019, 9, 9311.	1.6	9
34	Core elements of national cancer control plans: a tool to support plan development and review. Lancet Oncology, The, 2019, 20, e645-e652.	5.1	33
35	Radiotherapy underutilisation and its impact on local control and survival in New South Wales, Australia. Radiotherapy and Oncology, 2019, 141, 41-47.	0.3	16
36	OC-0158 Effect of EBRT underutilization in prostate cancer on overall survival and local control, NSW, Australia. Radiotherapy and Oncology, 2019, 133, S76.	0.3	0

#	Article	IF	Citations
37	OC-0599 Survival and local control deficits due to radiotherapy under-utilisation in NSW, Australia Radiotherapy and Oncology, 2019, 133, S314-S315.	0.3	1
38	Comparison of four methods for estimating actual radiotherapy utilisation using the 45 and Up Study cohort in New South Wales, Australia. Radiotherapy and Oncology, 2019, 131, 14-20.	0.3	7
39	Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact. Lancet Oncology, The, 2019, 20, 915-923.	5.1	45
40	Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncology, The, 2019, 20, 769-780.	5.1	128
41	Estimating the cost of radiotherapy for 5-year local control and overall survival benefit. Radiotherapy and Oncology, 2019, 136, 154-160.	0.3	11
42	Contributions of prognostic factors to socioeconomic disparities in cancer survival: protocol for analysis of a cohort with linked data. BMJ Open, 2019, 9, e030248.	0.8	3
43	Will We Still Need Radiotherapy in 20ÂYears?. , 2019, , 191-201.		1
44	The impact of imaging modality (CT vs MRI) and patient position (supine vs prone) on tangential whole breast radiation therapy planning. Practical Radiation Oncology, 2018, 8, e87-e97.	1.1	5
45	Estimating the number of fractions by tumour site for European countries in 2012 and 2025: An ESTRO-HERO analysis. Radiotherapy and Oncology, 2018, 126, 198-204.	0.3	13
46	The population benefit of evidence-based radiotherapy: 5-Year local control and overall survival benefits. Radiotherapy and Oncology, 2018, 126, 191-197.	0.3	71
47	3D printed phantoms mimicking cortical bone for the assessment of ultrashort echo time magnetic resonance imaging. Medical Physics, 2018, 45, 758-766.	1.6	21
48	Patient reported outcomes of slow, single arc rotation: Do we need rotating gantries?. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 553-561.	0.9	10
49	P1.15-25 Has Lung Cancer Radiotherapy Utilisation Changed over Time in New South Wales, Australia?. Journal of Thoracic Oncology, 2018, 13, S622.	0.5	0
50	What do undergraduate doctors really need to know about radiation oncology?. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 823-825.	0.9	1
51	MRI-Linear Accelerator Radiotherapy Systems. Clinical Oncology, 2018, 30, 686-691.	0.6	89
52	Quality of radiotherapy services in post-Soviet countries: An IAEA survey. Radiotherapy and Oncology, 2018, 127, 171-177.	0.3	2
53	Imaging performance of a dedicated radiation transparent RF coil on a 1.0 Tesla inline MRI-linac. Physics in Medicine and Biology, 2018, 63, 135005.	1.6	23
54	OC-0064: Estimating the cost benefit of radiotherapy for overall survival and local control. Radiotherapy and Oncology, 2018, 127, S28-S29.	0.3	0

#	Article	IF	Citations
55	Testing criterion-based benchmarking for the appropriate use of radiotherapy. Radiotherapy and Oncology, 2018, 128, 406-410.	0.3	7
56	Patterns of care and emergency presentations for people with non-small cell lung cancer in New South Wales, Australia: A population-based study. Lung Cancer, 2018, 122, 171-179.	0.9	16
57	Impact of radiotherapy underutilisation measured by survival shortfall, years of potential life lost and disability-adjusted life years lost in New South Wales, Australia. Radiotherapy and Oncology, 2018, 129, 191-195.	0.3	17
58	Radiotherapy utilization in developing countries: An IAEA study. Radiotherapy and Oncology, 2018, 128, 400-405.	0.3	31
59	A Look At Radiotherapy In Small Countries. , 2018, , .		0
60	Global Health in Radiation Oncology: The Emergence of a New Career Pathway. Seminars in Radiation Oncology, 2017, 27, 118-123.	1.0	18
61	Functional MRI for quantitative treatment response prediction in locally advanced rectal cancer. British Journal of Radiology, 2017, 90, 20151078.	1.0	56
62	Advancing access and equity: the vision of a new generation in cancer control. Lancet Oncology, The, 2017, 18, 172-175.	5.1	7
63	The Benefits of Providing External Beam Radiotherapy in Low- and Middle-income Countries. Clinical Oncology, 2017, 29, 72-83.	0.6	34
64	Trichodysplasia Spinulosa in a 7‥earâ€Old Boy Managed Using Physical Extraction of Keratin Spicules. Pediatric Dermatology, 2017, 34, e74-e76.	0.5	12
65	An MRIâ€compatible patient rotation system â€" design, construction, and first organ deformation results. Medical Physics, 2017, 44, 581-588.	1.6	26
66	Radiotherapy in Low- and Middle-income Countries. What Can We Do Differently?. Clinical Oncology, 2017, 29, 69-71.	0.6	15
67	PV-0092: Criterion-Based Benchmarking approach of the appropriate use of radiotherapy in NSW-ACT, Australia. Radiotherapy and Oncology, 2017, 123, S47-S48.	0.3	0
68	Radiotherapy in small countries. Cancer Epidemiology, 2017, 50, 257-259.	0.8	6
69	Global impact of radiotherapy in oncology: Saving one million lives by 2035. Radiotherapy and Oncology, 2017, 125, 175-177.	0.3	27
70	Cancer in small states – No small matter. Cancer Epidemiology, 2017, 50, 173-175.	0.8	3
71	Study protocol: multi-parametric magnetic resonance imaging for therapeutic response prediction in rectal cancer. BMC Cancer, 2017, 17, 465.	1.1	29
72	Hypofractionated versus conventionally fractionated radiotherapy for ductal carcinoma in situ ( <scp>DCIS</scp> ) of the breast. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 407-413.	0.9	6

#	Article	IF	CITATIONS
73	Global Access to Radiotherapy Services: Have We Made Progress During the Past Decade?. Journal of Global Oncology, 2016, 2, 207-215.	0.5	85
74	Technical Note: Experimental results from a prototype highâ€ield inline MRIâ€inac. Medical Physics, 2016, 43, 5188-5194.	1.6	43
75	Functional imaging equivalence and proof of concept for image-guided adaptive radiotherapy with fixed gantry and rotating couch. Advances in Radiation Oncology, 2016, 1, 365-372.	0.6	10
76	Radiation Therapy Utilization in Middle-Income Countries. International Journal of Radiation Oncology Biology Physics, 2016, 96, S37.	0.4	8
77	Global Access to Radiation Therapy for Cervical Cancer: The Cost of Inaction. International Journal of Radiation Oncology Biology Physics, 2016, 96, S14-S15.	0.4	2
78	The population benefit of radiotherapy for gynaecological cancer: Local control and survival estimates. Radiotherapy and Oncology, 2016, 120, 370-377.	0.3	11
79	Comparison of Magnetic Resonance Imaging and Computed Tomography for Breast Target Volume Delineation in Prone and Supine Positions. International Journal of Radiation Oncology Biology Physics, 2016, 96, 905-912.	0.4	18
80	The Population Benefit of Radiotherapy for Malignant Brain Tumors: Local Control and Survival Estimates for Guideline-Based Use. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1111-1119.	2.3	2
81	A Population-based Model of Local Control and Survival Benefit of Radiotherapy for Lung Cancer. Clinical Oncology, 2016, 28, 627-638.	0.6	28
82	Evidence-based optimal number of radiotherapy fractions for cancer: A useful tool to estimate radiotherapy demand. Radiotherapy and Oncology, 2016, 119, 145-149.	0.3	27
83	Estimation of the optimal utilisation rates of radical prostatectomy, external beam radiotherapy and brachytherapy in the treatment of prostate cancer by a review of clinical practice guidelines. Radiotherapy and Oncology, 2016, 118, 118-121.	0.3	10
84	How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiotherapy and Oncology, 2016, 119, 5-11.	0.3	122
85	Assessing Park-and-Ride Efficiency and User Reactions to Parking Management Strategies. Journal of Public Transportation, 2016, 19, 75-92.	0.3	12
86	Assessing the Gap Between Evidence Based Indications for Radiotherapy and Actual Practice in European Countries. Value in Health, 2015, 18, A481-A482.	0.1	2
87	Original paper Patterns of care study of brachytherapy in New South Wales: malignancies of the uterine corpus. Journal of Contemporary Brachytherapy, 2015, 3, 224-230.	0.4	5
88	Advances in radiation therapy. Medical Journal of Australia, 2015, 203, 394-395.	0.8	2
89	Estimation of an Optimal Chemotherapy Utilisation Rate for Upper Gastrointestinal Cancers: Setting an Evidence-Based Benchmark for the Best-Quality Cancer Care. Gastroenterology Research and Practice, 2015, 2015, 1-10.	0.7	4
90	The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. Radiotherapy and Oncology, 2015, 116, 45-50.	0.3	94

#	Article	IF	Citations
91	Australian survey on current practices for breast radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 736-742.	0.9	18
92	Radiation Therapy and the Global Health Agenda. Clinical Oncology, 2015, 27, 67-69.	0.6	8
93	The population benefit of radiotherapy for cervical cancer: Local control and survival estimates for optimally utilized radiotherapy and chemoradiation. Radiotherapy and Oncology, 2015, 114, 389-394.	0.3	26
94	The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiotherapy and Oncology, 2015, 116, 38-44.	0.3	131
95	Optimal radiotherapy utilisation rate in developing countries: An IAEA study. Radiotherapy and Oncology, 2015, 116, 35-37.	0.3	27
96	The Cancer, Lifestyle and Evaluation of Risk Study (CLEAR): Rationale and design of an unmatched "case-spouse control―study of over 10,000 participants in New South Wales, Australia. Cancer Epidemiology, 2015, 39, 414-423.	0.8	6
97	Factors Affecting the Use of Single-Fraction Radiotherapy for the Palliation of Bone Metastases in Australia. Clinical Oncology, 2015, 27, 205-212.	0.6	19
98	Global Task Force on Radiotherapy for Cancer Control. Lancet Oncology, The, 2015, 16, 1144-1146.	5.1	36
99	Expanding global access to radiotherapy. Lancet Oncology, The, 2015, 16, 1153-1186.	5.1	709
100	The effect of travel distance on radiotherapy utilization in NSW and ACT. Radiotherapy and Oncology, 2015, 117, 386-389.	0.3	42
101	Estimation of the optimal number of radiotherapy fractions for breast cancer: A review of the evidence. Radiotherapy and Oncology, 2015, 116, 174-178.	0.3	6
102	Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada: Results from two large cancer facilities. Cancer Epidemiology, 2015, 39, 600-611.	0.8	13
103	Evidence-based Estimates of the Demand for Radiotherapy. Clinical Oncology, 2015, 27, 70-76.	0.6	121
104	Prostate brachytherapy in New South Wales: patterns of care study and impact of caseload on treatment quality. Journal of Contemporary Brachytherapy, 2014, 4, 344-349.	0.4	4
105	Patterns of care study of brachytherapy in New South Wales: cervical cancer treatment quality depends on caseload. Journal of Contemporary Brachytherapy, 2014, 1, 28-32.	0.4	16
106	GlobalRT: building a new radiotherapy community. Lancet Oncology, The, 2014, 15, 926.	5.1	14
107	Patterns of Retreatment by Radiotherapy. Clinical Oncology, 2014, 26, 611-618.	0.6	24
108	Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012. Radiotherapy and Oncology, 2014, 112, 140-144.	0.3	387

#	Article	IF	CITATIONS
109	The Australian Magnetic Resonance Imaging–Linac Program. Seminars in Radiation Oncology, 2014, 24, 203-206.	1.0	299
110	Estimation of the Optimal Brachytherapy Utilization Rate in the Treatment of Gynecological Cancers and Comparison With Patterns of Care. International Journal of Radiation Oncology Biology Physics, 2013, 85, 400-405.	0.4	10
111	Poor Outcomes after Whole Brain Radiotherapy in Patients with Brain Metastases: Results from an International Multicentre Cohort Study. Clinical Oncology, 2013, 25, 674-680.	0.6	22
112	The varying role of the GP in the pathway between colonoscopy and surgery for colorectal cancer: a retrospective cohort study. BMJ Open, 2013, 3, e002325.	0.8	3
113	The Potential for an Enhanced Role for MRI in Radiation-Therapy Treatment Planning. Technology in Cancer Research and Treatment, 2013, 12, 429-446.	0.8	162
114	Referral pathways in colorectal cancer: an audit of surgeons's records. Australian Health Review, 2013, 37, 449.	0.5	2
115	Glioma of the Central Nervous System Surveillance Counterpoint: Australia., 2013,, 517-519.		O
116	Socio-demographic and other patient characteristics associated with time between colonoscopy and surgery, and choice of treatment centre for colorectal cancer: a retrospective cohort study. BMJ Open, 2012, 2, e001070.	0.8	12
117	Estimation of the optimal brachytherapy utilisation rate in the treatment of vaginal cancer and comparison with patterns of care. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 483-489.	0.9	6
118	Outcomes following treatment for patients with cranial nerve involvement from nasopharyngeal cancer. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 548-553.	0.9	5
119	Workforce shortages in medical oncology: a looming threat to quality cancer care. Medical Journal of Australia, 2012, 196, 32-33.	0.8	4
120	The shortage of medical oncologists: the Australian Medical Oncologist Workforce Study. Medical Journal of Australia, 2012, 196, 58-61.	0.8	45
121	A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal―therapy. Breast, 2012, 21, 562-569.	0.9	8
122	A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British) Tj ETQq0 0 0 rgBT Breast, 2012, 21, 570-577.	/Overlock 0.9	10 Tf 50 22 14
123	Chemotherapy in Rectal Cancer: Variation in Utilization and Development of an Evidence-based Benchmark Rate of Optimal Chemotherapy Utilization. Clinical Colorectal Cancer, 2011, 10, 102-107.	1.0	6
124	A decade of investment in radiotherapy in New South Wales: Why does the gap between optimal and actual persist?. Journal of Medical Imaging and Radiation Oncology, 2011, 55, 433-441.	0.9	24
125	Limited Chemotherapy and Shrinking Field Radiotherapy for Osteolymphoma (Primary Bone Lymphoma): Results From the Trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 Prospective Trial. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1164-1170.	0.4	33
126	Estimation of an Optimal Chemotherapy Utilisation Rate for Primary Malignant Brain Tumours: an Evidence-based Benchmark for Cancer Care. Clinical Oncology, 2011, 23, 48-54.	0.6	4

#	Article	IF	CITATIONS
127	Patterns of Retreatment by Radiotherapy. Clinical Oncology, 2011, 23, 10-18.	0.6	19
128	Estimation of an evidence-based benchmark for the optimal endocrine therapy utilization rate in breast cancer. Breast, 2010, 19, 345-349.	0.9	6
129	Estimation of an Optimal Utilisation Rate for Palliative Radiotherapy in Newly Diagnosed Cancer Patients. Clinical Oncology, 2010, 22, 56-64.	0.6	26
130	The Use of Categorized Time-Trend Reporting of Radiation Oncology Incidents: A Proactive Analytical Approach to Improving Quality and Safety Over Time. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1548-1554.	0.4	39
131	Estimation of an optimal chemotherapy utilisation rate for lung cancer: An evidence-based benchmark for cancer care. Lung Cancer, 2010, 69, 307-314.	0.9	19
132	Estimation of an optimal chemotherapy utilisation rate for breast cancer: Setting an evidence-based benchmark for the best-quality cancer care. European Journal of Cancer, 2010, 46, 703-712.	1.3	15
133	Management of skin toxicity during radiation therapy: A review of the evidence. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 264-279.	0.9	97
134	â€~GAP' in radiotherapy services in Australia and New Zealand in 2009. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 287-297.	0.9	12
135	Distance learning in the Applied Sciences of Oncology. Radiotherapy and Oncology, 2010, 95, 129-132.	0.3	17
136	The emergence of human uniqueness: Characters underlying behavioral modernity. Evolutionary Anthropology, 2009, 18, 187-200.	1.7	323
137	Advances in Cancer Management: At What Cost to Medical Student Education?. Journal of Cancer Education, 2009, 24, 233-237.	0.6	11
138	Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: Setting an evidence-based benchmark for the best-quality cancer care. European Journal of Cancer, 2009, 45, 2150-2159.	1.3	7
139	Estimation of an optimal chemotherapy utilisation rate for colon cancer: An evidence-based benchmark for cancer care. European Journal of Cancer, 2009, 45, 2503-2509.	1.3	5
140	Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. European Journal of Cancer, 2009, 45, 2510-2518.	1.3	50
141	An international review of patient safety measures in radiotherapy practice. Radiotherapy and Oncology, 2009, 92, 15-21.	0.3	113
142	A †Catch Up' Plan for radiotherapy in New South Wales to 2012. Journal of Medical Imaging and Radiation Oncology, 2009, 53, 419-430.	0.9	9
143	Do Cancer Follow-Up Consultations Create Anxiety?. Journal of Psychosocial Oncology, 2008, 26, 17-30.	0.6	10
144	Establishing treatment benchmarks for mammographyâ€screened breast cancer population based on a review of evidenceâ€based clinical guidelines. Cancer, 2008, 112, 1912-1922.	2.0	11

#	Article	IF	CITATIONS
145	Estimation of Optimal Brachytherapy Utilization Rate in the Treatment of Malignancies of the Uterine Corpus by a Review of Clinical Practice Guidelines and the Primary Evidence. International Journal of Radiation Oncology Biology Physics, 2008, 72, 849-858.	0.4	5
146	Continuing Medical Education Program in Echocardiography. Echocardiography, 2008, 25, 448-448.	0.3	0
147	Pressures of Crystallization of Icelandic Magmas. Journal of Petrology, 2008, 49, 465-492.	1.1	33
148	Cancer care in Australia. Biomedical Imaging and Intervention Journal, 2008, 4, e30.	0.5	2
149	Estimating the referral rate for cancer genetic assessment from a systematic review of the evidence. British Journal of Cancer, 2007, 96, 391-398.	2.9	13
150	Patterns of Radiotherapy Re-Treatment in Patients with Lung Cancer: A Retrospective, Longitudinal Study. Journal of Thoracic Oncology, 2007, 2, 531-536.	0.5	8
151	Cost analysis of Gamma Knife stereotactic radiosurgery. International Journal of Technology Assessment in Health Care, 2007, 23, 488-494.	0.2	13
152	An evidence-based estimation of local control and survival benefit of radiotherapy for breast cancer. Radiotherapy and Oncology, 2007, 84, 11-17.	0.3	26
153	Actual versus optimal utilization of radiotherapy in lung cancer: Where is the shortfall?. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 30-36.	0.7	9
154	Utilization of radiotherapy for rectal cancer in Greater Western Sydney 1994?2001. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 134-142.	0.7	0
155	Cancer knowledge and perception of skills of general practice registrars in Australia. Journal of Cancer Education, 2007, 22, 259-265.	0.6	4
156	Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncology, The, 2006, 7, 584-595.	5.1	249
157	What should doctors know about cancer? Undergraduate medical education from a societal perspective. Lancet Oncology, The, 2006, 7, 596-601.	5.1	55
158	Radiotherapy might not be the answer in Africa – Authors' reply. Lancet Oncology, The, 2006, 7, 705-706.	5.1	1
159	How not to effect change in curricula. Medical Journal of Australia, 2006, 185, 52-52.	0.8	5
160	SURGICAL PROCEDURES FOR MELANOMA IN PUBLIC AND PRIVATE NEW SOUTH WALES HOSPITALS, 2001-2002. ANZ Journal of Surgery, 2006, 76, 318-324.	0.3	5
161	Combined-modality therapy for primary central nervous system lymphoma: Long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). International Journal of Radiation Oncology Biology Physics, 2006, 64, 408-413.	0.4	86
162	Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines. Cancer, 2006, 106, 453-465.	2.0	12

#	Article	IF	Citations
163	Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix. Cancer, 2006, 107, 2932-2941.	2.0	20
164	The Ideal Oncology Curriculum for Medical Students. Journal of Clinical Oncology, 2006, 24, 5334-5334.	0.8	6
165	The Development of a New Basic Treatment Equivalent Model to Assess Linear Accelerator Throughput. Clinical Oncology, 2005, 17, 311-318.	0.6	11
166	Technology Enhancements and Changes in Radiotherapy Throughput in New South Wales. Clinical Oncology, 2005, 17, 305-310.	0.6	6
167	Socio-economic status and patterns of care in lung cancer. Australian and New Zealand Journal of Public Health, 2005, 29, 372-377.	0.8	33
168	Importance of radiation time and dose factors on outcome for childhood medulloblastoma*. Journal of Medical Imaging and Radiation Oncology, 2005, 49, 298-303.	0.6	11
169	Cancer curriculum in the Asia-Pacific: Opportunities and challenges in the age of globalization. Asia-Pacific Journal of Clinical Oncology, 2005, 1, 109-113.	0.7	1
170	Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence. Cancer, 2005, 103, 383-392.	2.0	15
171	Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence. Cancer, 2005, 103, 393-401.	2.0	33
172	Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies. Cancer, 2005, 103, 462-473.	2.0	38
173	Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma. Cancer, 2005, 103, 2216-2227.	2.0	38
174	Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma. Cancer, 2005, 104, 1221-1229.	2.0	107
175	The role of radiotherapy in cancer treatment. Cancer, 2005, 104, 1129-1137.	2.0	1,279
176	Achieving equal standards in medical student education: is a national exit examination the answer?. Medical Journal of Australia, 2005, 182, 228-230.	0.8	32
177	Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology, The, 2005, 6, 659-668.	5.1	876
178	Radiotherapy in Australia one year after the Baume report: vision or mirage?. Medical Journal of Australia, 2004, 180, 55-56.	0.8	58
179	Colorectal cancer patterns of care in the Western Sydney and Wentworth Area Health Services. ANZ Journal of Surgery, 2004, 74, 406-412.	0.3	13
180	Comparison of patterns of care in lung cancer in three area health services in New South Wales, Australia. Internal Medicine Journal, 2004, 34, 677-683.	0.5	30

#	Article	IF	Citations
181	Comparison of face-to-face and videoconferenced multidisciplinary clinical meetings. Journal of Medical Imaging and Radiation Oncology, 2004, 48, 487-492.	0.6	48
182	Estimation of an optimal radiotherapy utilization rate for melanoma. Cancer, 2004, 100, 1293-1301.	2.0	40
183	Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma. Cancer, 2004, 101, 657-670.	2.0	27
184	Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma. Cancer, 2004, 101, 671-681.	2.0	45
185	Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma. Cancer, 2004, 101, 682-692.	2.0	34
186	The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clinical Oncology, 2004, 16, 549-560.	0.6	173
187	Waiting times for radiotherapy—a survey of patients' attitudes. Radiotherapy and Oncology, 2004, 70, 283-289.	0.3	23
188	Evaluating Curriculum Changes in Undergraduate Cancer Education. Journal of Cancer Education, 2004, 19, 156-160.	0.6	17
189	Estimation of an optimal radiotherapy utilization rate for breast carcinoma. Cancer, 2003, 98, 1977-1986.	2.0	79
190	Sites of local recurrence after surgery, with or without chemotherapy, for rectal cancer: implications for radiotherapy field design. International Journal of Radiation Oncology Biology Physics, 2003, 55, 138-143.	0.4	48
191	Utility-adjusted analysis of the cost of palliative radiotherapy for bone metastases. Journal of Medical Imaging and Radiation Oncology, 2003, 47, 274-278.	0.6	22
192	A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncology, The, 2003, 4, 120-128.	5.1	101
193	Lung cancer patterns of care in south western Sydney, Australia. Thorax, 2003, 58, 690-694.	2.7	31
194	Cancer knowledge and skills of interns in Australia and New Zealand in 2001: comparison with 1990, and between course types. Medical Journal of Australia, 2003, 178, 285-289.	0.8	41
195	The Development of a Model of Outpatient Chemotherapy Delivery–Chemotherapy Basic Treatment Equivalent (CBTE). Clinical Oncology, 2002, 14, 406-412.	0.6	9
196	Modern radiotherapy for modern surgeons: An update on radiation oncology. ANZ Journal of Surgery, 2002, 72, 131-136.	0.3	3
197	The city and the bush: Where is the best place for radiotherapy departments?. Journal of Medical Imaging and Radiation Oncology, 2002, 46, 219-220.	0.6	3
198	A Basic Treatment Equivalent for High-Dose-Rate Gynaecological Brachytherapy–A Pilot Study. Clinical Oncology, 2002, 14, 394-398.	0.6	0

#	Article	IF	CITATIONS
199	REPLY TO GONZALEZ-SANSEGUNDO ET AL Radiotherapy and Oncology, 2001, 60, 333-334.	0.3	5
200	Palliative radiotherapy of bone metastases: an evaluation of outcome measures. Journal of Evaluation in Clinical Practice, 2001, 7, 47-64.	0.9	35
201	Radiotherapy utilization in New South Wales from 1996 to 1998. Journal of Medical Imaging and Radiation Oncology, 2000, 44, 308-314.	0.6	25
202	Mantle planning: Report of the Australasian Radiation Oncology Lymphoma Group film survey and consensus guidelines. Journal of Medical Imaging and Radiation Oncology, 2000, 44, 433-438.	0.6	8
203	Malignant retroperitoneal paraganglioma: Case report and review of treatment options. Journal of Medical Imaging and Radiation Oncology, 2000, 44, 478-482.	0.6	10
204	Phase II Multicenter Study of Brief Single-Agent Methotrexate Followed by Irradiation in Primary CNS Lymphoma. Journal of Clinical Oncology, 2000, 18, 519-519.	0.8	217
205	The effect of waiting for radiotherapy for grade III/IV gliomas. Radiotherapy and Oncology, 2000, 57, 131-136.	0.3	123
206	A survey of cancer curricula in Australian and New Zealand medical schools in 1997. Medical Journal of Australia, 1999, 170, 225-227.	0.8	27
207	ADJUVANT THERAPY FOR RECTAL CANCER CAN NO LONGER BE IGNORED. ANZ Journal of Surgery, 1999, 69, 619-621.	0.3	0
208	Osteolymphoma (primary bone lymphoma): an Australian review of 70 cases. Australian and New Zealand Journal of Medicine, 1999, 29, 214-219.	0.5	33
209	Radiotherapy for Bone Metastases. Journal of Pain and Symptom Management, 1999, 17, 208-218.	0.6	19
210	The Doses Received by the Breast During Mantle Radiotherapy. International Journal of Radiation Oncology Biology Physics, 1998, 41, 223-226.	0.4	13
211	Delays in referral for palliative radiotherapy. Medical Journal of Australia, 1998, 169, 12-13.	0.8	3
212	Does waiting time affect the outcome of larynx cancer treated by radiotherapy?. Radiotherapy and Oncology, 1997, 44, 137-141.	0.3	69
213	Health outcomes and radiation therapy: A new era of competition. Journal of Medical Imaging and Radiation Oncology, 1997, 41, 1-2.	0.6	0
214	Sucralfate cream in the management of moist desquamation during radiotherapy. Journal of Medical Imaging and Radiation Oncology, 1997, 41, 270-275.	0.6	46
215	Radiotherapy for early infradiaphragmatic Hodgkin's disease: the Australasian experience. Radiotherapy and Oncology, 1996, 39, 1-7.	0.3	14
216	Multicentre dosimetry study of mantle treatment in Australia and New Zealand. Radiotherapy and Oncology, 1996, 40, 171-180.	0.3	21

#	Article	IF	Citations
217	Primary bone lymphoma (osteolymphoma). Journal of Medical Imaging and Radiation Oncology, 1996, 40, 319-323.	0.6	10
218	Radiation therapy for early stage Hodgkin's disease: Australasian patterns of care. International Journal of Radiation Oncology Biology Physics, 1995, 31, 227-236.	0.4	19
219	Oropharyngeal cancer in the elderly. International Journal of Radiation Oncology Biology Physics, 1995, 32, 1007-1016.	0.4	49
220	Radiation therapy: Are we getting value for money?. Clinical Oncology, 1995, 7, 287-292.	0.6	37
221	Tables of equivalent dose in 2 gy fractions: A simple application of the linear quadratic formula. International Journal of Radiation Oncology Biology Physics, 1995, 31, 371-378.	0.4	75
222	Split-course accelerated therapy in head and neck cancer: An analysis of toxicity. International Journal of Radiation Oncology Biology Physics, 1995, 32, 763-768.	0.4	26
223	The use of poorly validated and expensive technology. Medical Journal of Australia, 1994, 160, 799-799.	0.8	3
224	Influence of radiotherapy treatment time on control of laryngeal cancer: comparisons between centres in Manchester, UK and Toronto, Canada. Radiotherapy and Oncology, 1994, 31, 14-22.	0.3	59
225	The use of poorly validated and expensive technology. Medical Journal of Australia, 1994, 161, 726-726.	0.8	0
226	Response to Dr. B. Jones et al Radiotherapy and Oncology, 1993, 28, 180.	0.3	3
227	The effect of treatment duration in the local control of cervix cancer. Radiotherapy and Oncology, 1992, 25, 273-279.	0.3	347
228	Reply to letter by Drs. Dubray and Thames. Radiotherapy and Oncology, 1992, 23, 200.	0.3	0
229	The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. Radiotherapy and Oncology, 1992, 23, 137-143.	0.3	206
230	The effect of treatment duration on local control of squamous carcinoma of the tonsil and carcinoma of the cervix. Seminars in Radiation Oncology, 1992, 2, 26-28.	1.0	42